McAdam LLC’s Adamas Pharmaceuticals ADMS Stock Holding History

McAdam LLC’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-300	Closed	-$6K	–	687
2018 Q3	$6K	Buy	+300	New	+$7.04K	﹤0.01%	401

Other funds holding ADMS

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

McAdam LLC's ADMS Position: Q4 2018 in Review

McAdam LLC sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 300 shares — an estimated $6K sold.

McAdam LLC first reported a position in ADMS in Q3 2018 and held it in 1 quarter. The position peaked at $6K in Q3 2018. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

McAdam LLC reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
McAdam LLC sold 300 Adamas Pharmaceuticals shares in Q4 2018, an estimated $6K.
McAdam LLC first reported a position in Adamas Pharmaceuticals in Q3 2018 and held it in 1 quarter.
McAdam LLC's Adamas Pharmaceuticals position peaked at $6K in Q3 2018.
98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.